In an attempt to identify and characterize novel Schwann cell surface molecules with putative functions during development, maintenance, and regeneration of the peripheral nervous system (PNS), we have produced monoclonal antibodies against viable neonatal rat Schwann cells. Using a sensitive live c
Phenotypic characterization of ‘non-T, non-B’ acute lymphoblastic leukemia by a new panel (BL) of monoclonal antibodies
✍ Scribed by Ayad Al-Katib; Chang Yi Wang; Ricardo Bardales; Benjamin Koziner
- Publisher
- John Wiley and Sons
- Year
- 1985
- Tongue
- English
- Weight
- 739 KB
- Volume
- 3
- Category
- Article
- ISSN
- 0278-0232
No coin nor oath required. For personal study only.
✦ Synopsis
Peripheral blood and/or bone marrow leukemic cell suspensions from 49 patients with 'non-T, non-B' acute lymphoblastic leukemia (ALL) were analysed by flow cytometry using a new panel of four monoclonal antibodies. Anti-BL1 and anti-BL2 originating from NALM-6 and B35M lymphoblastoid cell lines, respectively. These antibodies recognize B-cell differentiation antigens: a heat stable non-immunoprecipitable antigenic determinant, and a 68 000 daltons glycoprotein molecule, respectively. BL5 and BL6 were derived by immunization with the promyelocytic cell line HL-60, recognizing antigens present on early hematopoietic cells: an 85 000 daltons MW glycoprotein (Pro-Iml) and a heat stable antigen (Pro-ImZ), respectively. A11 ALL patients studied had LI or L2 morphology by the FAB classification and a blast count exceeding 50 per cent. There were 25 males and 24 females. Median age was 8 years (range 1-67 years). Thirty-nine cases were studied at initial presentation and 10 at relapse. Cells from 46/49 cases expressed BL2 and/or BL1, but were not reactive with BL5 or BL6. Three of 49 cases did not express BL1 or BL2. However, a small percentage of blasts from one case was positive for BL5 (13 per cent) and the other 2 cases were reactive with BL6 (20 per cent and 36 per cent, respectively). These were one adult and 2 pediatric patients that had other ALL markers and achieved a complete remission with appropriate ALL therapy. One of the BL6 + cases relapsed after 19 months with a change in phenotype to BL1+ BL2 + BL5 -BL6 -. This analysis shows that the majority of 'non-T, non-B ALL'S do express B-cell associated antigens (BLl/BL2) argumentative of their B a l l origin. A small subgroup does not express such antigens and may arise from a more immature cell, since they expressed antigens on early hematopoietic stem cells.
📜 SIMILAR VOLUMES
One hundred six children with newly diagnosed non-T-, non-B-cell acute lymphoblastic leukemia (ALL) were treated in a Pediatric Oncology Group (POG) pilot study in which six courses of intermediate-dose methotrexate (MTX) and cytosine arabinoside (Ara-C) (1 g/m2 each) were added to a "backbone" of s